Formación de Circuitos Neuronales y enfermedades cerebrales

La alta complejidad del cerebro no sólo se debe a los billones de neuronas de muy diverso tipo que lo conforman y que se conectan para formar las redes neuronales, sino que depende también de las conexiones sinápticas dinámicas que se establecen durante la vida del organismo. Con nuestro trabajo pretendemos estudiar los mecanismos moleculares que controlan el desarrollo y la formación de sinapsis de las neuronas inhibitorias, tanto en la corteza cerebral como en el núcleo estriado. El entendimiento de estos mecanismos es esencial ya que son la base de ciertos desórdenes y enfermedades neurológicas tales como la Esquizofrenia, el síndrome de Rett o la enfermedad de Huntington.

Investigador Principal del Grupo

Dr. Rubén Deogracias Pastor
Investigador Ramón y Cajal
Producción Científica

Personal Adscrito

Natalia Varela Andrés
Investigadora Predoctoral

Alejandro Cebrián León
Investigador predoctoral

Sandra García Losada
Técnico superior de laboratorio

Lucía Soriano Moreno
Estudiante de fin de máster

Carlos Hernández del Cano
Estudiante de máster

Publicaciones

  1. Distinct molecular programs regulate synapse specificity in cortical inhibitory circuits. Deogracias R*, Favuzzi E*, Marques-Smith A, Maeso P, Jezequel J, Exposito-Alonso D, Balia M , Kroon T, Hinojosa AJ, Maraver EF, Rico B. *Equal contribution. Science. 2019.
  2. The Microtubule Regulator NEK7 Coordinates the Wiring of Cortical Parvalbumin Interneurons. Hinojosa AJ, Deogracias R, Rico B. Cell Reports. 2018
  3. Activity-Dependent Gating of Parvalbumin Interneuron Function by the Perineuronal Net Protein Brevican. Favuzzi E, Deogracias R*, Marques-Smith A*, Winterflood CM, Sánchez-Aguilera A, Mantoan L, Maeso P, Fernandes C, Ewers H, Rico B. *Equal contribution.  Neuron. 2017.
  4. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Deogracias R*, Yazdani M*, Dekkers MP, Guy J, Ionescu MC, Vogt KE, Barde YA. *Equal contribution. PNAS. 2012.
  5. Seizure-induced neuronal death is suppressed in the absence of the endogenous lectin Galectin1. Deogracias R*, Bischoff V, Poirier F, Barde Y-A.  *Equal contribution. J Neurosci. 2012. 
  6. Disease modeling using embryonic stem cells: MeCP2 regulates nuclear size and RNA synthesis in neurons. Deogracias R*, Yazdani M*, Guy J, Poot RA, Bird A, Barde Y-A.  *Equal contribution. Stem Cells. 2012.
  7. Topoisomerase IIβ binding to promoters in postmitotic cells modulates gene activity and regulates neuronal survival. Tiwari W, Burger L#, Nikoletopoulou V#, Deogracias R, Wirbelauer C, Murr R, Terranova R, Mielke. C, Boege F, Lyu Y-L, Peters A, Barde Y-A, Schübeler D. *Equal contribution. PNAS. 2012.
  8. BDNF and its pro-peptide are stored in presynaptic large dense core vesicles in brain neurons. Dieni S, Matsumoto T, Dekkers M, Rauskolb S, Ionescu M, Deogracias R, Gundelfinger E-D, Kojima M, Nestel S, Frotscher M, Barde Y-A. The Journal of Cell Biology. 2012. 
  9. Imbalance of neurotrophin receptor isoforms TrkB-FL/TrkB-T1 induces neuronal death in excitotoxicity. Vidaurre O-G#, Gascón S#, Deogracias R, Sobrado M, Cuadrado E, Montaner J, Rodríguez-Peña A, and M. Díaz-Guerra. #Equal contribution. Cell Death and Disease. 2012.
  10. Global deprivation of brain-derived neurotrophic factor in the CNS reveals an area-specific requirement for dendritic growth. Rauskolb S, Zagrebelsky M, Dreznjak A, Deogracias R, Matsumoto T, Wiese S, Erne B, Sendtner M, Schaeren-Wiemers, Korte M and Barde Y-A. J Neurosci. 2010.

Proyectos Vigentes

Proyecto de Investigación: PID2020-113086RB-I00. Ministerio de Ciencia e Innovación. 163,350€.

Voces Internas durante el desarrollo de las neuronas GABAérgicas / Inner Voices of the Development of GABAergic neurons (InVoDeGa).

Patentes

Genetic modification Site – application number: PCT/GB2020/051906. Abstract: This invention relates to genetic engineering, in particular to an insertion site for a transgene, cells comprising a transgene or other modification at that insertion site, vectors for targeting that insertion site, and methods for creating transgenic cells by insertion or other modification at that site. Inventors: Randolph CORTELING, Rubén DEOGRACIAS. Applicant: RENEURON LIMITED  Type: Application. Filed: 10 August 2020. Issued: February 18, 2021.

2. Use of S1P Receptor Modulator – application number: 20140235610. Abstract: Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression. Inventors: Yves-Alain BARDE, Graeme BILBE, Ruben Deogracias, Rainer R. KUHN, Tomoya MATSUMOTO, Anis Khusro MIR, Anna Svenja SCHUBART. Applicants: Novartis AG Type: Application Filed: December 5, 2013 Issued: August 21, 2014.

3. Use of S1P Receptor Modulator – application number: 20140011884. Abstract: Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression. Inventors: Yves-Alain BARDE, Graeme BILBE, Ruben Deogracias, Rainer R. KUHN, Tomoya MATSUMOTO, Anis Khusro MIR, Anna Svenja SCHUBART. Applicants: Novartis AG Type: Application Filed: May 13, 2013 Issued: January 9, 2014.

4. Use of S1P Receptor Modulator – application number: 20120245129. Abstract: Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression. Inventors: Yves-Alain BARDE, Graeme BILBE, Ruben Deogracias, Rainer R. KUHN, Tomoya MATSUMOTO, Anis Khusro MIR, Anna Svenja SCHUBART. Applicants: Novartis AG Type: Application Filed: December 5, 2011 Issued: September 27, 2012

5. Use of S1P Receptor Modulator – application number: 20100093672. Abstract: Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression. Inventors: Yves-Alain BARDE, Graeme BILBE, Ruben Deogracias, Rainer R. KUHN, Tomoya MATSUMOTO, Anis Khusro MIR, Anna Svenja SCHUBART. Applicants: Novartis AG Type: Application Filed: December May 1, 2008 Issued: April 15, 2010.

A %d blogueros les gusta esto: